Annovis Bio, Inc. ANVS
0.75 USD -0.09 (-11.01%)
Regular-session close
0.77 +0.03 +3.42%
After hours · Nov 19, 5:46 PM ET
0.7236 Day range 0.8293
0.62 52-week range 5.50
- YTD
- -78.37%
- 1 year
- -77.86%
Benzinga news
benzinga.com Annovis Bio Receives Second Consecutive Positive Recommendation From Independent Data And Safety Monitoring Board For Its DUET-AD Phase 3 Trial In Early Alzheimer's Disease; Six-Month Topline Results On Track For March 2027 This 12-month review follows the DSMB’s positive 6-month feedback, which was announced in February 2026. The DSMB recommended that DUET-AD continue without modification, based on the data accumulated…
benzinga.com Roth Capital Reiterates Buy on Annovis Bio, Lowers Price Target to $3 Roth Capital analyst Boobalan Pachaiyappan reiterates Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $7 to $3.
benzinga.com Annovis Bio Q3 EPS $(0.22) Beats $(0.32) Estimate Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.32) by 31.25 percent. This is a 40.54 percent increase over losses of $(0.37)…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Lakewood-Amedex (NASDAQ:LABT) shares moved upwards by 237.6% to $0.65 during Thursday's regular session. ADMA Biologics (NASDAQ:ADMA) stock increased by 25.62% to $13.16. The market value of…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers ADMA Biologics (NASDAQ:ADMA) shares rose 19.6% to $12.53 during Thursday's pre-market session. The market value of their outstanding shares is at $2.3 billion. As per the news, the Q3…benzinga.com Annovis Bio Plans To Commence Common Stock Offering; Terms Undisclosed Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases…
benzinga.com Annovis Bio Obtains Noncompliance Notice From NYSE Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such…
